Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod

被引：4
作者：
Zhang, Chaoyue [1 ]
Lin, Yangtao [1 ]
Kuang, Qianjin [1 ]
Li, Hongjin [1 ]
Jiang, Qilong [1 ]
Yang, Xiaojun [1 ]
机构：
[1] Guangzhou Univ Chinese Med, Affiliated Hosp Chinese Med 1, Guangzhou, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
myasthenia gravis; telitacicept; efgartigimod; highly active; refractory; case report; BELIMUMAB; ANTIBODY; EFFICACY; SAFETY; BAFF;
D O I：
10.3389/fimmu.2024.1400459
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which brings promising therapeutic strategies. We report a case of a 37-year-old female patient with refractory GMG, whose condition got significant improvement and control with this latest treatment after multiple unsuccessful therapies of immunosuppressants. The new combination deserves further attention in the therapeutic application of myasthenia gravis.
引用
收藏
页数：6
相关论文
共 24 条
  • [1] The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)
    Allen, Nicholas M.
    O'Rahelly, Mark
    Eymard, Bruno
    Chouchane, Mondher
    Hahn, Andreas
    Kearns, Gerry
    Kim, Dae-Seong
    Byun, Shin Yun
    Nguyen, Cam-Tu Emilie
    Schara-Schmidt, Ulrike
    Koelbel, Heike
    Della Marina, Adela
    Schneider-Gold, Christiane
    Roefke, Kathryn
    Thieme, Andrea
    Van den Bergh, Peter
    Avalos, Gloria
    Alvarez-Velasco, Rodrigo
    Natera-de Benito, Daniel
    Cheng, Man Hin Mark
    Chan, Wing Ki
    Wan, Hoi Shan
    Thomas, Mary Ann
    Borch, Lauren
    Lauzon, Julie
    Kornblum, Cornelia
    Reimann, Jens
    Mueller, Andreas
    Kuntzer, Thierry
    Norwood, Fiona
    Ramdas, Sithara
    Jacobson, Leslie W.
    Jie, Xiaobo
    Fernandez-Garcia, Miguel A.
    Wraige, Elizabeth
    Lim, Ming
    Lin, Jean Pierre
    Claeys, Kristl G.
    Aktas, Selma
    Oskoui, Maryam
    Hacohen, Yael
    Masud, Ameneh
    Leite, M. Isabel
    Palace, Jacqueline
    De Vivo, Darryl
    Vincent, Angela
    Jungbluth, Heinz
    [J]. BRAIN, 2023, 146 (10) : 4233 - 4246
  • [2] Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status
    Beecher, Grayson
    Putko, Brendan Nicholas
    Wagner, Amanda Nicole
    Siddiqi, Zaeem Azfer
    [J]. DRUGS, 2019, 79 (04) : 353 - 364
  • [3] Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis
    Chen, Xia
    Zhao, Qian
    Hou, Yong
    Jiang, Ji
    Zhong, Wen
    Wang, Wenxiang
    Yao, Xuejing
    Li, Lin
    Fang, Jianmin
    Zhang, Fengchun
    Hu, Pei
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 41 - 52
  • [4] Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies
    Chen, Xin
    Qiu, Jiayi
    Gao, Zihui
    Liu, Boya
    Zhang, Chen
    Yu, Weiran
    Yang, Jiawen
    Shen, Yuntian
    Qi, Lei
    Yao, Xinlei
    Sun, Hualin
    Yang, Xiaoming
    [J]. BIOCHEMICAL PHARMACOLOGY, 2023, 218
  • [5] Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells
    Cornelis, Rebecca
    Chang, Hyun-Dong
    Radbruch, Andreas
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2021, 71 : 97 - 102
  • [6] Immunotherapy in myasthenia gravis in the era of biologics
    Dalakas, Marinos C.
    [J]. NATURE REVIEWS NEUROLOGY, 2019, 15 (02) : 113 - 124
  • [7] Conventional and emerging treatments and controversies in myasthenia gravis
    Evoli, Amelia
    Damato, Valentina
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (05) : 445 - 456
  • [8] Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
    Fichtner, Miriam L.
    Hoehn, Kenneth B.
    Ford, Easton E.
    Mane-Damas, Marina
    Oh, Sangwook
    Waters, Patrick
    Payne, Aimee S.
    Smith, Melissa L.
    Watson, Corey T.
    Losen, Mario
    Martinez-Martinez, Pilar
    Nowak, Richard J.
    Kleinstein, Steven H.
    O'Connor, Kevin C.
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2022, 10 (01)
  • [9] Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
    Hewett, Karen
    Sanders, Donald B.
    Grove, Richard A.
    Broderick, Christine L.
    Rudo, Todd J.
    Bassiri, Ashlyn
    Zvartau-Hind, Marina
    Bril, Vera
    [J]. NEUROLOGY, 2018, 90 (16) : E1425 - E1434
  • [10] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
    Howard, James F. Jr Jr
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Perk, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    [J]. LANCET NEUROLOGY, 2021, 20 (07) : 526 - 536
123